AEON Biopharma, Inc. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
On November 2, 2026, AEON Biopharma amended its two-year milestone warrants (issued July 15, 2026) with consent from holders representing ≥67% of outstanding warrant shares. Exercise price reduced from $0.3221 to $0.20 per share for common stock; pre-funded warrant exercise price set at $0.1999. Amendment applies to all outstanding warrants regardless of individual holder consent. Counterparties unnamed; total warrant share count not specified in filing.
Why this rating
Material dilution risk to $8.7M company: 38% price cut substantially increases warrant exercise incentive and future equity dilution, directly threatening shareholder value at micro-cap scale.
Tradability signal
NO TRADE
No trade: price $0.27 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $0.29 ▲ 6.63% | at our read · unknown $0.27 | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
The stock had already moved -6.22% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.